Skip to content
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
featured-image

Press Release

RapidAI Celebrates International Adoption of AI-Powered Stroke Care

The company today announced unprecedented growth in the adoption and use of the Rapid platform around the world with nearly 300% growth. San Mateo, Calif. — November 12, 2020 — RapidAI, the leader in advanced imaging for stroke, today announced unprecedented growth in the adoption and use of the Rapid platform around the world. Now approved in over 60 countries and utilized in over 1,600 hospitals, the company has experienced a year-over-year increase in just International Rapid scans (outside the U.S.) of nearly 300%, comparing Q3 2019 to Q3 2020. RapidAI makes the most-widely used advanced cerebrovascular imaging products for patient care, research, and clinical trials across the globe. RapidAI clinical products help save lives, RapidAI workflow and messaging technologies help stroke teams save time, and RapidAI analytics and business intelligence products help stroke networks reduce costs and improve patient outcomes. “The number of people who suffer a stroke worldwide each year is staggering, over fifteen million,” offered Marc Hofmans RapidAI Senior Vice President of Sales, EMEA. “While it is no small task, our mission is to bring AI-powered stroke imaging to every corner of the globe. With Rapid now in more than 60 countries, we are well on our way.” After celebrating the one-millionth Rapid scan in July of this year, RapidAI now reports that it is on an accelerating run-rate to deliver one-million scans in 2020, alone. With the goal of saving lives and improving the outcomes for more and more patients, RapidAI is also on track to reach the major milestone of a million total patients scanned by the end of this year. RapidAI International Growth Rapid in use in over 1,600 hospitals worldwide Rapid now in more than 60 countries 298% growth in Rapid scans, outside the U.S., (Q3 2019 to Q3 2020) 275% growth in patients scanned with Rapid, outside the U.S., (Q3 2019 to Q3 2020) Run-rate to deliver one-million Rapid scans worldwide in 2020 On track to scan a total of one-million patients worldwide, with Rapid, by the end of 2020 “ I see artificial intelligence as the future in the fast-moving world of diagnostic and therapeutic stroke management,” said Dr. Sanjeev Nayak, Royal Stoke NHS UK. “Using AI will help stroke victims when 'Time Is Brain'. RapidAI has helped stroke patients by providing positive insight to the treating clinicians by accelerating stroke diagnosis. This ensures accurate therapeutic intervention in the shortest possible time after the onset of stroke. ” Rapid is the only clinically validated platform available and considered by many to be the gold standard for advanced cerebrovascular imaging. To learn more visit www.RapidAI.com . About RapidAI RapidAI is the worldwide leader in advanced imaging for stroke. Based on intelligence gained over 1,000,000 scans from more than 1,600 hospitals in over 60 countries, the Rapid® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview®, a comprehensive aneurysm management platform. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically-proven, data-driven technology. With our validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day. For more information, visit RapidAI.com.
featured-image

Press Release

Penumbra Announces Partnership with RapidAI

The companies will work to develop clinical and communications modules for pulmonary embolism, a deadly condition involving blood clots in the lungs. Alameda, Calif. — November 10, 2020 —Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced a new partnership to develop solutions to enable faster clinical decision-making for pulmonary embolism (PE) diagnosis and procedures with RapidAI, a company that offers a clinically proven, data-driven artificial intelligence (AI) platform that empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients. “PE is at the precipice of a transformation in how patients affected by this condition are being treated. Several advances have been made during the last few years largely due to the PERT Consortium’s efforts, combined with innovation in therapeutic options,“ said Robert Lookstein, MD MHCDL FSIR FAHA FSVM, president of the PERT Consortium, professor of Radiology and Surgery at Icahn School of Medicine at Mount Sinai (ISMMS) and executive vice chairman in The Department of Diagnostic, Molecular, and Interventional Radiology for the Mount Sinai Health System. “This exciting new partnership will undoubtedly help bring more awareness to this very deadly disease. The entire field wants to rapidly bring more therapeutic options to a broader segment of the population. We collectively believe this will only improve outcomes.” Penumbra and RapidAI will work together to develop several clinical and communications modules for pulmonary embolism, which is a deadly condition involving blood clots in the lungs. The modules are aimed to streamline triage and decision-making by processing CT scans and delivering clear, easy-to-interpret CT images directly to the physician. In addition, this partnership comes at a very important time, as the medical community is dealing with the COVID-19 pandemic where patient triage and remote access have become critical to the healthcare system. “COVID-19 has heightened the need for AI technology that powers physicians’ ability to be connected to their healthcare institutions and care teams from remote locations and to speed up patient care,” said Don Listwin, chief executive officer, Rapid AI. “We are thrilled to be partnering with one of the most innovative medical device companies, Penumbra, to advance the field of PE by rising to these challenges with our powerful AI solutions.” This new partnership with RapidAI demonstrates Penumbra’s continued commitment to advancing solutions for pulmonary embolism and follows the recent launch of the Indigo® System with Lightning™ Intelligent Aspiration, Penumbra’s newest generation technology for the removal of blood clots in the arteries and veins and for the treatment of pulmonary embolism. “Penumbra has been at the forefront of technology to address unmet clinical needs - be it in stroke, virtual rehab, intelligent aspiration and now pulmonary embolism,” said Adam Elsesser, chairman and chief executive officer, Penumbra Inc. “This partnership with RapidAI is another example of Penumbra’s commitment to provide cutting-edge solutions that help address the challenges faced by the medical community. We look forward to taking on this next frontier in the field of PE.” About Penumbra Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra sells its products to hospitals and healthcare providers primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets. Penumbra, the Penumbra P logo, Indigo, and Lightning are trademarks of Penumbra, Inc. For more information, visit www.penumbrainc.com. About RapidAI RapidAI is the worldwide leader in advanced imaging for stroke. Based on intelligence gained over 1 million scans from more than 1,600 hospitals in over 50 countries, the Rapid® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview®, a comprehensive aneurysm management platform. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically proven, data-driven technology. With its validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day. For more information, visit www.rapidai.com . Forward-Looking Statements Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the impact of the COVID-19 pandemic on our business, results of operation and financial condition; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; and potential adverse regulatory actions. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 26, 2020, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the SEC on May 7, 2020, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the SEC on August 3, 2020 and our Quarterly Report on Form 10-Q for the quarter September 30, 2020 filed with the SEC on November 2, 2020. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
featured-image

Press Release

RapidAI Among the First Stroke Imaging Software Technologies Approved for Medicare New Technology Add-on Payment

Stroke Imaging Makes Significant Stride in Reimbursement. Helps U.S. Hospitals More Easily Adopt the Latest Advancements in Stroke Care San Mateo, Calif. — October 1, 2020 — RapidAI, the worldwide leader in advanced imaging for stroke, today announced Rapid LVO is among the first software products to qualify for the New Technology Add-on Payment (NTAP). NTAP is part of the CMS Inpatient Prospective Payment System (IPPS). A significant advancement in stroke care and reimbursement for Medicare patients, the news further fuels the expansion of advanced stroke imaging for those technologies that meet the NTAP requirements, foremost Rapid LVO from RapidAI. The new NTAP program applies to LVO triage and notification for stroke. Rapid LVO explicitly meets the definition of measuring arterial blood flow in the brain per the issued NTAP code definition. RapidAI offers the most comprehensive stroke imaging platform available. O nce an LVO (Large Vessel Occlusion) is identified, Rapid ASPECTS can quantify the severity of the stroke, and Rapid CTP or Rapid MRI can then notify a stroke team if a patient is eligible for thrombectomy. “Our mission can be simply stated…save lives, save time and save money,” said Don Listwin, CEO of RapidAI. “This exciting new development in Medicare reimbursement may at first seem like just a bookkeeping issue or just a win for RapidAI, the industry leader. However, in truth, this is not a step forward for any one company, but instead an advancement for various software technologies with the end goals of saving more lives and enabling better patient outcomes.” RapidAI makes the most-widely used stroke imaging software for patient care, research, and clinical trials—helping hospitals around the world save time, money, and lives. Rapid is the only clinically validated platform available and considered by many to be the gold standard for advanced cerebrovascular imaging. To learn more visit www.RapidAI.com .
featured-image

Press Release

RapidAI Announces $25 Million in Series B Funding

Funding Will be Used to Expand AI-Enhanced Cerebrovascular Imaging Worldwide San Mateo, Calif. — September 17, 2020 – RapidAI, the worldwide leader in advanced imaging for stroke, today announced a $25 million Series B round of funding by Lennertz & Co. Building on years of profitability, these additional funds will accelerate the company’s strategic growth initiatives around the world. Founded in 2011, RapidAI makes the most-widely used advanced cerebrovascular imaging products for patient care, research, and clinical trials. This funding will support the continued advancement of the Rapid ® platform and world-class clinical products. RapidAI clinical products help save lives, RapidAI workflow and messaging technologies help stroke teams save time, and RapidAI analytics and business intelligence products help stroke networks reduce costs and improve patient outcomes. “For several years, we have worked to develop and bring to market the next generation of AI-enhanced cerebrovascular imaging products. We have been rewarded for that dedication with sustained growth and uninterrupted profitability since going to market,” said Don Listwin, CEO of RapidAI. “In the last year, we have expanded our scope from ischemic stroke to hemorrhagic stroke, and with the recent acquisition of EndoVantage, we now address aneurysm. In these difficult global times, t his investment is a significant sign of support, that while others are shrinking and shuttering, we are investing and growing to help build efficient stroke networks across multi-site systems and referral networks.” RapidAI offers an end-to-end portfolio of advanced stroke imaging and stroke assessment products for hospitals of all sizes. The Rapid platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans, helping hospitals to speed up time-critical triage or transfer decisions and facilitate better patient outcomes. “We want our investment monies directed toward companies and teams that demonstrate global vision and a track record of success,” said Philipp Lennertz, Managing Director of Lennertz & Co. "RapidAI’s vision to massively improve stroke and other cerebrovascular care through AI, and other medical imaging innovations, has known no borders and brought measurable improvement to patient care worldwide. We are excited to help them continue and expand on their mission.” “Since RapidAI cofounders, Dr. Albers and Dr. Bammer, presented research that dramatically grew stroke treatment guidelines globally, thousands of other clinicians and I have been able to address more patients and achieve better outcomes,” said Dr. Olav Jansen, Professor at the Department of Radiology and Neuroradiology, UKSH Campus Kiel, Kiel, Germany. “With the Rapid platform’s wide array of AI-enhanced imaging technologies, we have seen opportunities for effective care grow daily.” About RapidAI RapidAI is the worldwide leader in advanced imaging for stroke. Based on intelligence gained over 1,000,000 scans from more than 1,600 hospitals in over 50 countries, the Rapid ® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview ® , a comprehensive aneurysm management platform. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically-proven, data-driven technology. With our validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day. For more information, visit RapidAI.com .
featured-image

Press Release

RapidAI Launches Rapid Web App and Receives ISO 27001 Certification

The ISO 27001 Certification Signifies High Level of Data Security and Management San Mateo, Calif. — September 10, 2020 – RapidAI, the worldwide leader in advanced imaging for stroke, today announced the launch of the Rapid Web App as well as ISO 27001 data security and management certification. The addition of the Rapid Web App delivers another way for stroke teams to conveniently preview and interact with Rapid ® results and communicate securely. In parallel RapidAI’s ISO 27001 certification acknowledges the company’s significant security and privacy protection protocols. The new Rapid Web App extends access into yet another user environment, offering stroke team members a convenient way to view real-time browser notifications of new cases, preview Rapid results and source files, and enable workflow communications via a desktop or laptop. The app works with Google Chrome and Microsoft Edge browsers to give users an easy way to view, organize, and track cases from multiple sites in one location. “It takes a whole team to treat stroke and we want to ensure our tools meet the team where they are – whether on a phone, desktop, or a laptop,” said Rachel Witalec, Vice President of Product at RapidAI. “With the Rapid Web App team members now have even more ways to ensure they can collaborate and preview time-sensitive stroke imaging across their workflow.” With the Rapid Web App Stay updated: The Rapid Web App delivers new case information to physicians through browser notifications. It saves precious time by giving users the option to preview Rapid results and compressed patient images directly from a desktop or laptop. Faster treatment decisions: The powerful Rapid clinical backend delivers processed imaging results based on NCCT, CTP, CTA and MRI (diffusion and perfusion) scans to the Rapid Web App in minutes. The app helps facilitate faster treatment decisions by giving physicians the ability to immediately preview Rapid results and source files through the built-in Image viewer. Streamlining patient care: The Rapid Web App’s collaboration features facilitate and accelerate acute care coordination. Stroke team members can communicate within the app—centralizing case information, communicating team activation, limiting touchpoints, and reducing miscommunications. Secure, Compliant Access & Communications: The Rapid Web App is integrated with third-party identity providers such as Microsoft Active Directory to support single sign-on and easier activation and deactivation of Rapid Web App accounts. The secure, GDPR and HIPAA-compliant Rapid Web App provides the tools hospitals need to support stroke-care operations. Data security & compliance with ISO 27001 Building on RapidAI’s commitment to secure and compliant data management, today the company also announced it has received ISO 27001 certification, a rigorous information security standard that demonstrates RapidAI’s investment in the people, processes, and technology to protect its platform and data. In addition to a National Institute of Standards and Technology (NIST) cybersecurity framework, RapidAI is HIPAA compliant, GDPR compliant, ISO 13485 and ISO 27001 certified. RapidAI makes the most-widely used stroke imaging software for patient care, research, and clinical trials—helping hospitals around the world save time, money, and lives. Rapid is the only clinically validated platform available and considered by many to be the gold standard for advanced cerebrovascular imaging. To learn more visit www.RapidAI.com . About RapidAI RapidAI is the worldwide leader in advanced imaging for stroke. Based on intelligence gained over 1,000,000 scans from more than 1,600 hospitals in over 50 countries, the Rapid ® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview ® , a comprehensive aneurysm management platform. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically-proven, data-driven technology. With our validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day. For more information, visit RapidAI.com .
featured-image

Press Release

RapidAI Receives FDA Clearance of Rapid LVO

For Identification of Suspected Large Vessel Occlusions Menlo Park, Calif. — August 13, 2020 –RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Rapid LVO has received Food and Drug Administration (FDA) clearance for detecting suspected LVOs (Large Vessel Occlusions). Rapid LVO helps physicians speed up triage or transfer decision-making. Working in as few as 3 minutes, Rapid LVO uses a vessel tracker in conjunction with assessment of brain regions with reduced blood vessel density to identify suspected LVOs with a sensitivity of 97% and a specificity of 96%. Stroke team members are also immediately notified when a suspected LVO is detected. “LVOs are the most disabling and deadly ischemic strokes,” said Dr. Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of RapidAI. “The ability to identify LVOs rapidly facilitates more effective treatment. This is why we are very excited about the FDA clearance of Rapid LVO, a significant step forward in stroke diagnostics and care.” RapidAI makes the most-widely used stroke imaging software for patient care, research, and clinical trials—helping hospitals around the world save time, money, and lives. Rapid ® is the only clinically validated platform available and considered by many to be the gold standard for advanced cerebrovascular imaging. To learn more visit www.RapidAI.com/Rapid-CTA . About RapidAI RapidAI is the worldwide leader in advanced imaging for stroke. Based on intelligence gained over 1,000,000 scans from more than 1,600 hospitals in over 50 countries, the Rapid ® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview ® , a comprehensive aneurysm management platform. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically-proven, data-driven technology. With our validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day.
featured-image

Press Release

RapidAI Celebrates One-Millionth Scan

Thomas Jefferson University Hospital Recognized for One-Millionth Recorded Rapid® Scan Menlo Park, Calif. — July 28, 2020 — RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Thomas Jefferson University Hospital in Philadelphia was the site of the one-millionth recorded Rapid ® scan. Building on its leadership in AI-powered stroke imaging, with this news RapidAI fortifies its standing as the most widely used, clinically validated stroke imaging software for patient care, research, and clinical trials. Based on intelligence gained from an unmatched 1,000,000+ scans from more than 1,600 hospitals in over 50 countries, the artificial intelligence-based Rapid platform creates high-quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The platform offers an end-to-end portfolio of advanced cerebrovascular imaging analysis products—including Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid CTP, and Rapid MRI. Now, with over one million scans, RapidAI can leverage even more statistical power and data to enhance performance and improve patient care at individual hospitals as well as larger networks and systems around the world. With its region-wide reputation for quality stroke care, Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, has been awarded the distinction of the one-millionth recorded Rapid scan. “Stroke imaging and care have evolved quickly over the last couple of years, thanks in large part to innovations from the likes of RapidAI as well as expanded AHA/ASA stroke guidelines,” said Pascal Jabbour, MD, Professor of Neurological Surgery and the Chief of the Division of Neurovascular and Endovascular Neurosurgery in the Department of Neurological Surgery at the Sidney Kimmel Medical College at Thomas Jefferson University. “We are gratified to be the site of the one-millionth Rapid scan as we are always in pursuit of the tools, techniques and intelligence that lead to better patient outcomes.” The complete Rapid platform currently includes: Rapid ICH: automatically triages non-contrast CT scans to quickly identify brain Rapid ASPECTS: automatically identifies areas of early ischemic change on non-contrast CT scans, which predicts irreversible injury Rapid CTA: automatically assesses regions of reduced blood flow to identify, locate, and alert stroke teams to the presence of large vessel occlusions (LVOs) Rapid CTP: fully-automated perfusion maps; accurately quantifies reduced cerebral blood flow, cerebral blood volume and transit time Rapid MRI: fully-automated diffusion and perfusion maps that quantify brain areas with low ADC values, as well as delayed contrast arrival Rapid Mobile App: securely preview RapidAI results from multiple sites, receive notifications, and communicate about patient care, anytime, anywhere "It is with great excitement that we honor Thomas Jefferson University Hospital for the one millionth recorded Rapid scan. In parallel, this builds on the over 1,600 hospitals in the U.S. and around the world that rely on RapidAI technology as an integral part of their stroke care every day,” said Don Listwin, CEO of RapidAI. “Also, with the aggregate data of over one million scans, along with predictive algorithms and our RapidAI Insights analytics solution, we can help benchmark data, performance and clinical workflow for single hospital sites and whole networks, improving everyone’s stroke IQ.”
featured-image

Press Release

Leader in Stroke Imaging Introduces RapidAI Insights

New Analytics Platform Delivers Hospitals A Comprehensive View Into Their Stroke Imaging, Patient Care and Business Menlo Park, Calif. — June 16, 2020 — RapidAI, the worldwide leader in advanced imaging for stroke, today announced the launch of RapidAI Insights. A unique new analytics platform, RapidAI Insights presents Rapid® scan, treatment, and outcomes data to help hospitals and systems make more-informed business decisions, reduce costs across sites, while simultaneously improving patient outcomes, and saving more lives. RapidAI Insights offers a portfolio of analytic reports and is a valuable solution for multi-site systems and referral networks looking to standardize stroke care processes and optimize operational efficiencies. RapidAI Insights Optimizes operational efficiency and effectiveness: RapidAI Insights provides multi-site systems with the intelligence to help monitor the adoption of Rapid products and evaluate return-on-investment (ROI) across sites. Improves processes for emergent stroke care: By combining operational, clinical, and imaging data, RapidAI Insights offers customized reports to deliver deep insights on patient care decisions, treatment effectiveness, and platform usage quality in helping to quickly diagnose and treat stroke patients leading to faster intervention and improved patient outcomes. Increases usage and improves scan protocols: RapidAI Insights enables hospitals to monitor the usage of the Rapid platform by site and proactively ensure proper and consistent use of Rapid products across sites. Enables easier data monitoring and security: RapidAI Insights gives hospital IT and security team members peace of mind on who has access to and is using Rapid products. “At RapidAI we focus on helping hospitals save lives, save time and save money," said Don Listwin, CEO of RapidAI. “Developed with intelligence from over 1,500 sites already using Rapid, RapidAI Insights utilizes the massive amount of critical site and system-wide stroke imaging data to deliver hospitals a best-in-class analytic tool that informs their patient care, as well as the economics of their stroke care business. RapidAI Insights addresses the needs of clinicians, IT departments, and hospital administrators." RapidAI Insights Reports Include Rapid Stats and Usage Insights: A suite of reports that offer data on Rapid utilization, scan details and demographics, and scan quality. Executive Insights: An executive-level report that offers an information-rich summary of site-specific information across systems for those looking to optimize operational efficiencies and reduce costs. Security and Monitoring Insights: Designed to help hospitals support best practices in security, monitoring and compliance auditing; the Security and Monitoring Insights provide IT teams with information on Rapid Mobile App access and usage. Patient Journey and Clinical Outcomes Insights: A customized report that delivers hospitals a detailed view into the patient journey and clinical outcomes to help drive stroke protocol improvements. "As an Interventional Neuroradiologist for a large system, I understand the tremendous value in seeing stroke imaging metrics across patients and our dozens of hospitals in multiple states," said Daniel P. Gibson, MD, and Director, Neurointerventional Surgery. "Analytics coming out of RapidAI Insights help us better understand the opportunities and challenges, which greatly benefit our patients, from the timeliness of care to informing how we handle transfer decisions. In parallel, it also helps our administrators better understand our work from a business perspective."
featured-image

Press Release

Rapid ASPECTS First Neuroimaging Solution with CADx FDA Clearance

AI-Powered Stroke Imaging Solution First to Receive FDA Advanced CADx Clearance to Raise Reading Capabilities for Non-Expert Readers Menlo Park, Calif. — June 16, 2020 —RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Rapid ASPECTS has received Food and Drug Administration (FDA) clearance as the first neuroimaging analysis device in the CADx (Computer-Assisted Diagnostic software) category. Rapid ASPECTS is the only neuroimaging product shown to improve physicians’ interpretations of Non-Contrast CT (NCCT) scans using a standardized ASPECT score. Validated through the rigorous FDA process, the use of Rapid ASPECTS automated score combined with the physician’s review of the scan, improves the accuracy of the ASPECT score calculation which is particularly important for less experienced readers. Based on the Alberta Stroke Program Early CT Scoring (ASPECTS) system, Rapid ASPECTS uses a validated machine-learning algorithm to automatically identify the ASPECTS regions of the brain and generate an ASPECT score to indicate early signs of brain infarction on NCCT scans—helping physicians identify areas of irreversible brain injury. By automating and standardizing this process, Rapid ASPECTS helps stroke teams across hospital sites and referral networks quickly assess patient eligibility for thrombectomy—enabling faster triage and transfer decisions that facilitate better patient outcomes. “Rapid ASPECTS represents the next AI-powered step forward in stroke imaging, and the groundbreaking CADx clearance from the FDA puts it in a class by itself,” said Dr. Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of RapidAI. “In addition to helping stroke teams with faster triage and transfer decisions, Rapid ASPECTS also improves the accuracy of typical readers.” Rapid ASPECTS Provides: Standardized, predictive assessment: In a few minutes, Rapid ASPECTS automatically delivers a standardized ASPECT score—assisting physicians to quickly identify areas of irreversible injury and help determine a patient’s eligibility for thrombectomy. Validated Machine-Learning Intelligence: Rapid ASPECTS delivers fast measurements utilizing a sophisticated, machine-learning algorithm that has been validated in clinical research studies. Faster Triage or Transfer Decisions: Rapid ASPECTS supports collaboration between hospitals and specialists to make faster triage and transfer decisions for patients—helping to facilitate better patient care and outcomes. “The FDA’s advanced CADx clearance has never been granted to a neuroimaging solution before,” said Jim Rosa, Senior Vice President of Regulatory and Clinical at RapidAI. “Through a combination of clinically validated advances in AI and machine learning, Rapid ASPECTS offers a glimpse into the future of stroke imaging.” RapidAI is the most-widely used stroke imaging software for patient care, research, and clinical trials—helping hospitals around the world save time, money, and lives. It is the only clinically validated platform available and the gold standard for advanced cerebrovascular imaging. Based on intelligence gained from over 650,000+ scans from more than 1,500 hospitals in over 50 countries, the artificial intelligence-based Rapid ® platform creates high-quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The platform offers an end-to-end portfolio of advanced cerebrovascular imaging analysis products—including Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid CTP, and Rapid MRI. Already in use internationally, Rapid ASPECTS will be commercially available in the U.S. later this month. To learn more, visit rapidai.com/rapid-aspects.
3 4 5 6 7